Small Molecule Orphan Drugs: Status Quo, Challenges & Perspectives

Although approximately 1,500 compounds with orphan drug designation are currently in development, an estimated one-third are unlikely to reach the market. This underscores the importance of proactively addressing the challenges that can hinder the successful development and commercialization of orphan therapies.

From limited patient populations and complex manufacturing requirements to tight timelines and regulatory considerations, orphan drug programs often face unique obstacles that can impact progress if not carefully managed. Implementing a well-defined and effective development strategy is therefore critical to navigating these complexities and ensuring the production of a safe, high-quality drug product for patients in need.

One of the most effective ways to mitigate risk is through thoughtful process design and strategic planning early in the development journey. By establishing robust manufacturing processes and scalable production strategies from the outset, developers can help de-risk orphan drug production, improve efficiency, and position their programs for greater long-term success.